Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 11/20 | 0.57 |
| ▸ | XDH | P47989 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 2/20 | 0.48 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575266 | 1.00 | HPRT1 (0.57) | HPRT1XDHPNPTYMPBLM | |
| SCHEMBL27041198 | 0.85 | HPRT1 (0.40) | HPRT1TYMPMEN1LMNAKMT2A | |
| SCHEMBL27041175 | 0.85 | HPRT1 (0.40) | HPRT1TYMPMEN1LMNAKMT2A | |
| SCHEMBL27041171 | 0.85 | HPRT1 (0.40) | HPRT1TYMPMEN1LMNAKMT2A | |
| SCHEMBL2577678 | 0.84 | CTSK (0.50) | HPRT1XDHTYMPLMNA | |
| SCHEMBL2577674 | 0.84 | CTSK (0.50) | HPRT1XDHTYMPLMNA | |
| SCHEMBL2577682 | 0.84 | CTSK (0.50) | HPRT1XDHTYMPLMNA | |
| SCHEMBL2567895 | 0.81 | NSD3 (0.52) | ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL14955424 | 0.81 | NSD3 (0.52) | ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL14955845 | 0.80 | MGMT (0.42) | TYMPMEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2011133876-A2 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | NSUN2, BCDIN3D, ADAR | HPRT1 165/4885XDH 1824/4885PNP 240/4885 |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ADAR, TYMS, POLM | HPRT1 33/4885XDH 1674/4885PNP 80/4885 |
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | NSUN2, BCDIN3D, RNGTT | HPRT1 195/4885XDH 1715/4885PNP 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.